PURPOSE: To report the external ocular changes in 2 patients receiving epidermal growth factor receptor (EGFR) inhibitors. METHODS: Retrospective observational case series. Two patients receiving epidermal growth factor inhibitors for metastatic non-small-cell lung carcinoma were followed clinically and with external photographs. RESULTS: Findings included acneiform facial changes, telangiectasia of eyelid margins, meibomitis, tear film dysfunction, and unusual, hyperpigmented, tortuous eyelashes. CONCLUSIONS: EGFR inhibitors used in the treatment of certain malignancies can lead to symptomatic adnexal and ocular surface changes. Ophthalmologists should be aware of these to appropriately manage them.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2007) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: